Key Events This Week
2 Feb: Stock hits 52-week and all-time low at Rs.392.05
3 Feb: Further 52-week low recorded at Rs.385.15 amid technical deterioration
6 Feb: Q3 FY26 results reveal sharp profit decline raising concerns
6 Feb: Week closes at Rs.403.05, up 1.05% for the week
Monday, 2 February 2026: New 52-Week and All-Time Low Amid Market Resilience
Medi Assist Healthcare Services Ltd’s stock opened the week under pressure, hitting a fresh 52-week and all-time low of Rs.392.05. The stock declined by 2.11% to close at Rs.390.45, underperforming the Sensex which fell 1.03% that day. Despite the broader market’s mixed performance, the stock’s technical indicators remained weak, trading below all key moving averages. The company’s rising interest expenses and a 51.0% drop in quarterly profit before tax excluding other income weighed heavily on investor sentiment.
Tuesday, 3 February 2026: Further Decline to Rs.385.15 Despite Gap-Up Opening
On 3 February, the stock opened with a positive gap, rising to an intraday high of Rs.406.60, but ultimately closed at a new 52-week low of Rs.385.15, down 6.67% from the previous close. This day’s decline contrasted with the broader market’s volatility, as the Sensex closed down 2.87%. Technical momentum deteriorated further, with the stock trading below its 20-day and longer-term moving averages. The company’s Mojo Score dropped to 19.0, reflecting a Strong Sell rating amid rising concerns over profitability and valuation.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Wednesday, 4 February 2026: Mild Recovery Amid Mixed Technical Signals
The stock rebounded modestly on 4 February, gaining 1.01% to close at Rs.414.85. This uptick was accompanied by a slight improvement in short-term technical indicators, although the stock remained below its 20-day and longer-term moving averages. The broader Sensex also advanced 0.37%, reflecting a generally positive market mood. Despite this, the underlying fundamentals remained under pressure, with the company’s interest expenses continuing to rise sharply.
Thursday, 5 February 2026: Renewed Selling Pressure and Technical Deterioration
On 5 February, the stock declined 1.60% to Rs.408.20, reversing some of the previous day’s gains. Technical momentum worsened as the stock fell below its 5-day moving average again, and bearish indicators such as the weekly MACD and KST remained intact. The Sensex also retreated 0.53%, reflecting some profit-taking in the broader market. The stock’s underperformance relative to the benchmark persisted, signalling ongoing investor caution.
Friday, 6 February 2026: Q3 FY26 Results Disappoint, Stock Closes Slightly Higher
Medi Assist Healthcare Services Ltd reported a sharp profit decline in its Q3 FY26 results, raising concerns over rising costs and profitability. The company’s profit before tax excluding other income fell by 51.0% to Rs.11.19 crores, while interest expenses surged 182.12% to Rs.16.73 crores over nine months. Despite these challenges, the stock closed the week at Rs.403.05, up 1.05% for the day and the week, marginally underperforming the Sensex’s 1.51% gain. The market’s muted reaction suggests cautious optimism tempered by fundamental headwinds.
Is Medi Assist Healthcare Services Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Daily Price Performance: Medi Assist Healthcare Services Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-02 | Rs.390.45 | -2.11% | 35,814.09 | -1.03% |
| 2026-02-03 | Rs.410.70 | +5.19% | 36,755.96 | +2.63% |
| 2026-02-04 | Rs.414.85 | +1.01% | 36,890.21 | +0.37% |
| 2026-02-05 | Rs.408.20 | -1.60% | 36,695.11 | -0.53% |
| 2026-02-06 | Rs.403.05 | -1.26% | 36,730.20 | +0.10% |
Key Takeaways from the Week
1. Persistent Downtrend and Valuation Pressure: The stock hit new 52-week and all-time lows early in the week, reflecting sustained selling pressure amid rising interest expenses and declining core profitability. The price-to-book ratio remains elevated at 5.1 despite weak earnings, contributing to cautious investor sentiment.
2. Technical Momentum Mixed but Bearish: While a brief recovery on 4 February showed some short-term strength, the overall technical picture remains bearish with the stock trading below key moving averages and negative MACD and KST indicators. The weekly RSI hints at possible short-term relief but lacks confirmation from volume and longer-term momentum.
3. Earnings Disappointment: The Q3 FY26 results revealed a sharp 51.0% decline in profit before tax excluding other income and a significant rise in interest costs, raising concerns about the company’s ability to sustain earnings growth amid cost pressures.
4. Relative Underperformance: Medi Assist underperformed the Sensex throughout the week and over longer timeframes, with one-year returns around -32% compared to the Sensex’s positive gains, highlighting sector-specific or company-specific challenges.
5. Strong Sell Rating Maintained: The Mojo Score deteriorated to 19.0 with a Strong Sell grade, reflecting the combination of fundamental weaknesses and technical deterioration. This rating signals continued caution among market analysts and participants.
Conclusion
Medi Assist Healthcare Services Ltd’s week was characterised by volatility and fundamental challenges. Despite a modest weekly gain of 1.05%, the stock remains under pressure from rising interest expenses, declining profitability, and bearish technical indicators. The fresh 52-week lows and all-time low prices early in the week underscore the stock’s vulnerability, while the Q3 FY26 results have heightened concerns about near-term earnings sustainability. Although some short-term technical signals suggest limited relief, the overall outlook remains cautious with a Strong Sell rating maintained. Investors should monitor the stock’s ability to stabilise earnings and improve technical momentum before considering renewed exposure.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
